Form 4: Sangamo Therapeutics CFO Reports Stock Transactions Following RSU Vesting
SEC Form 4
Prathyusha Duraibabu, CFO of Sangamo Therapeutics, reports disposition of shares for tax withholding purposes following RSU vesting, along with the grant of new stock options and RSUs.
Summary
- On February 24, 2025, Prathyusha Duraibabu, the SVP and CFO of Sangamo Therapeutics, surrendered 1,792 shares of common stock to the issuer for tax withholding purposes at a price of $1.00 per share, following the vesting of a portion of a restricted stock unit (RSU) grant.
- On February 25, 2025, Duraibabu surrendered 1,375 shares for tax withholding at $0.9561 per share following another RSU vesting.
- Also on February 25, 2025, Duraibabu acquired 120,000 shares of common stock through a new RSU grant.
- Additionally, Duraibabu acquired options to purchase 560,000 shares of common stock at an exercise price of $0.9561, exercisable starting February 24, 2035.
- Following these transactions, Duraibabu directly owns 811,803 shares of Sangamo Therapeutics common stock and holds options for 560,000 shares.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The filing primarily reflects routine transactions related to equity compensation. The acquisition of new shares and options is a slightly positive signal, but the disposal of shares for tax purposes is a neutral event.
Positives
- The grant of 120,000 shares via RSU and options to purchase 560,000 shares indicates continued investment in the company by the CFO.
- The vesting schedule of the new RSU and option grants incentivizes long-term commitment from the CFO.
Future Outlook
The reporting person's remaining RSUs will continue to vest in quarterly installments through February 24, 2026, and January 22, 2026, subject to continuous service.
Industry Context
Form 4 filings are routine disclosures required by the SEC to provide transparency regarding insider transactions. They are closely watched by investors to gauge management's sentiment and confidence in the company's prospects.
Stakeholder Impact
- The transactions have a minor impact on shareholders, as they involve a relatively small number of shares compared to the total outstanding.
- Employees holding similar equity grants may experience similar tax withholding events upon vesting.
Key Dates
| Date | Description |
|---|---|
| 02/25/2022 | Date of previous RSU grant that vested in final quarterly installments on February 25, 2025 |
| 02/24/2023 | Date of previous RSU grant that will vest in successive equal quarterly installments through February 24, 2026 |
| 01/22/2024 | Date of previous RSU grant that will vest in successive equal quarterly installments through January 22, 2026 |
| 02/24/2025 | Date of RSU vesting and share disposal for tax withholding. |
| 02/25/2025 | Date of RSU vesting, share disposal for tax withholding, and new RSU and option grants. |
| 02/26/2025 | Date of signature on the Form 4 filing. |
| 02/24/2035 | Expiration date of the stock options granted on February 25, 2025. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.